GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (OTCPK:RVXCF) » Definitions » Interest Coverage

RVXCF (Resverlogix) Interest Coverage : 0 (At Loss) (As of Sep. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Resverlogix Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Resverlogix's Operating Income for the three months ended in Sep. 2024 was $-1.05 Mil. Resverlogix's Interest Expense for the three months ended in Sep. 2024 was $-0.82 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Resverlogix's Interest Coverage or its related term are showing as below:


RVXCF's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 137.08
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Resverlogix Interest Coverage Historical Data

The historical data trend for Resverlogix's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Resverlogix Interest Coverage Chart

Resverlogix Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Resverlogix Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Resverlogix's Interest Coverage

For the Biotechnology subindustry, Resverlogix's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resverlogix's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Resverlogix's Interest Coverage falls into.



Resverlogix Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Resverlogix's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Resverlogix's Interest Expense was $-1.83 Mil. Its Operating Income was $-6.21 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Resverlogix did not have earnings to cover the interest expense.

Resverlogix's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Here, for the three months ended in Sep. 2024, Resverlogix's Interest Expense was $-0.82 Mil. Its Operating Income was $-1.05 Mil. And its Long-Term Debt & Capital Lease Obligation was $8.13 Mil.

Resverlogix did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Resverlogix  (OTCPK:RVXCF) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Resverlogix Interest Coverage Related Terms

Thank you for viewing the detailed overview of Resverlogix's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Resverlogix Business Description

Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Resverlogix Headlines

From GuruFocus

Resverlogix Provides Update Regarding Extension of its Filing Calendar

By GlobeNewswire GlobeNewswire 09-12-2020

Resverlogix Corp. - Special Call Transcript

By GuruFocus Research 02-14-2024

Resverlogix Announces One-Year Extension of Debenture

By GlobeNewswire GlobeNewswire 04-19-2022

Resverlogix Corp. - Special Call Transcript

By GuruFocus Research 02-14-2024

Resverlogix Reschedules Update Webcast and Conference Call

By GlobeNewswire GlobeNewswire 01-27-2021

Resverlogix Corp Annual Shareholders Meeting Transcript

By GuruFocus Research 02-14-2024

Resverlogix Corp. - Special Call Transcript

By GuruFocus Research 02-14-2024

Resverlogix Announces Proposed Offering of Units

By GlobeNewswire GlobeNewswire 05-14-2019

Resverlogix to Host BETonMACE Webcast and Conference Call

By GlobeNewswire GlobeNewswire 09-27-2019